Search

everythinglearnresearchcommunity

for

Search:↓

Switching from finasteride to dutasteride and oral minoxidil led to thicker hair and reduced hairline recession. Occasional flushing from minoxidil will be managed by lowering the dose.

The conversation discusses hair loss and treatments, with users suggesting the original poster's hair has receded despite using a dermaroller and RU58841 for two months. Many recommend starting finasteride and minoxidil for better results.

User questions credibility of a hair loss "cure" found by a non-expert and warns against wasting money on unproven supplements. Others discuss trying natural extracts and the importance of researching the enzyme 3ADH for potential hair growth benefits.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

A new hair loss treatment shows promise in mice but is unproven in humans. Effective treatments include finasteride and minoxidil.

PP405, a potential treatment for male pattern baldness, shows promise with some participants experiencing hair regrowth in early trials. However, it is not yet considered a cure and may be used alongside existing treatments like minoxidil and finasteride.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.